Tags: breast | cancer | gene | test | 23andMe

23andMe Gets OK to Sell Breast Cancer Gene Test

23andMe Gets OK to Sell Breast Cancer Gene Test
(Copyright DPC)

Tuesday, 06 March 2018 01:46 PM

The U.S. Food and Drug Administration on Tuesday allowed genetic testing company 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.

The drug regulator said the test, which work by analyzing DNA collected from saliva samples, provides genetic risk information but cannot determine a person's overall risk of developing a disease or condition.

The test detects only three out of more than 1,000 known BRCA mutations and are not the most common ones in the general population, the drug regulator said.

BRCA mutations account for about 50 percent of hereditary breast cancers and up to 65 percent of those who inherit the mutations will develop breast cancer.

The regulator said it reviewed data for the company's test under a regulatory pathway for low-to-moderate risk devices that are not equivalent to an already marketed device.

The agency also set a condition known as special controls, clarifying its expectations for assuring test accuracy and reliability.

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Cancer
The FDA has allowed 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.
breast, cancer, gene, test, 23andMe
166
2018-46-06
Tuesday, 06 March 2018 01:46 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved